Medicare AdvantageCoverageMedium impact
MA08.057d, Belimumab (Benlysta®) for Intravenous Use
Independence Blue Cross·Rheumatology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.057d for Belimumab (Benlysta®) intravenous use has been reissued and will become effective May 28, 2025. This is a pharmacy policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for this specialty medication used primarily in rheumatology.
Action Required
Before May 28, 2025: Billing team should review the updated Belimumab (Benlysta®) policy at the provided URL to identify any changes to prior authorization requirements, coverage criteria, or billing procedures for Medicare Advantage patients. Update billing system and provider workflows accordingly to ensure compliance with the new policy requirements.